Protalix Biotherapeutics Inc (PLX) Sees Large Decline in Short Interest
Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) was the target of a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 2,514,282 shares, a drop of 61.1% from the November 30th total of 6,457,835 shares. Currently, 1.9% of the shares of the company are short sold. Based on an average trading volume of 685,794 shares, the days-to-cover ratio is presently 3.7 days.
An institutional investor recently bought a new position in Protalix Biotherapeutics stock. OxFORD Asset Management LLP acquired a new stake in Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 687,796 shares of the company’s stock, valued at approximately $576,000. OxFORD Asset Management LLP owned 0.54% of Protalix Biotherapeutics at the end of the most recent reporting period.
Shares of Protalix Biotherapeutics (NYSEAMERICAN PLX) opened at $0.66 on Thursday. Protalix Biotherapeutics has a fifty-two week low of $0.35 and a fifty-two week high of $1.51. The stock has a market cap of $318.44, a price-to-earnings ratio of -0.33 and a beta of 0.98.
Several brokerages have recently commented on PLX. Zacks Investment Research downgraded shares of Protalix Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, December 20th. HC Wainwright set a $5.00 price objective on shares of Protalix Biotherapeutics and gave the company a “buy” rating in a research report on Wednesday, November 29th. Finally, BidaskClub downgraded shares of Protalix Biotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, December 2nd.
Protalix Biotherapeutics Company Profile
Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease.
Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.